Keveyis

Drug Overview

In the specialized field of Endocrinology and neuromuscular metabolic health, the management of electrolyte-driven disorders requires highly precise pharmacological intervention. Keveyis is a potent medication utilized to stabilize patients suffering from rare, debilitating episodes of muscle weakness. It belongs to the Drug Class known as Carbonic Anhydrase Inhibitors. While this class is often associated with glaucoma or altitude sickness, Keveyis is uniquely tailored for metabolic stabilization in the context of muscle ion channel function.

Keveyis serves as a critical Targeted Therapy for individuals whose metabolic pathways fail to maintain the necessary electrical balance across muscle cell membranes. By modulating systemic pH and electrolyte excretion, it helps prevent the sudden onset of paralysis that characterizes certain hereditary metabolic conditions.

• Generic Name: Dichlorphenamide
• US Brand Names: Keveyis
• Route of Administration: Oral (Tablet)
• FDA Approval Status: FDA-approved for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Keveyis functions, one must examine the molecular relationship between blood chemistry and muscle excitability. Muscle contraction relies on a precise balance of potassium ions moving across cell membranes. In patients with periodic paralysis, genetic mutations in ion channels cause the muscle cells to become “electrically silent” when potassium levels shift, leading to temporary paralysis.

Keveyis works at the molecular level by inhibiting the enzyme carbonic anhydrase. This enzyme is responsible for the conversion of carbon dioxide and water into bicarbonate and hydrogen ions. By blocking this enzyme, particularly in the renal tubules of the kidney, Keveyis promotes the excretion of bicarbonate in the urine. This loss of bicarbonate creates a state of mild non-anion gap metabolic acidosis.

This systemic shift in pH is the key to its therapeutic effect. The mild acidity encourages the movement of potassium out of the cells or alters the sensitivity of the faulty ion channels to potassium shifts. Specifically, the metabolic acidosis helps to keep the muscle cell membrane potential in a range that prevents “depolarization block”—the state where muscles become unresponsive. Unlike Hormone Replacement Therapy which adds missing substances, Keveyis acts as a metabolic modulator, recalibrating the internal environment to ensure that electrical signals can still trigger muscle movement despite underlying genetic defects.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Keveyis is the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and variant forms of these conditions. It is specifically used to reduce the frequency and severity of paralytic attacks.

Other Approved & Off-Label Uses

While its primary role is in periodic paralysis, the chemical properties of dichlorphenamide have broader applications in metabolic and fluid management:

• Primary Endocrinology Indications:
  • Management of metabolic alkalosis (off-label), where the drug helps restore pH balance by promoting bicarbonate loss.
  • Stabilization of serum potassium fluctuations in patients with secondary periodic paralysis related to adrenal or thyroid dysfunction (adjunctive use).
• Non-Endocrine Uses: Historically used for the treatment of open-angle or secondary glaucoma by reducing aqueous humor secretion.

Dosage and Administration Protocols

Dosing for Keveyis must be carefully titrated to balance the prevention of paralytic attacks against the development of excessive metabolic acidosis or electrolyte depletion.

Indication	Standard Dose	Frequency
Hyperkalemic/Hypokalemic Periodic Paralysis	50 mg (Initial)	Twice daily
Maintenance Titration	50 mg to 100 mg	Two to three times daily
Maximum Recommended Dose	200 mg total	Daily limit

Administration Details:

• Initial Phase: Treatment typically begins at 50 mg twice daily. The dose is adjusted based on the patient’s individual attack frequency.
• Titration: Changes to the dose should occur at intervals of 1 to 2 weeks to allow the body’s metabolic markers to stabilize.
• Renal/Hepatic Insufficiency: Keveyis is contraindicated in patients with severe hepatic or renal failure. For patients with mild-to-moderate renal impairment, extreme caution and frequent electrolyte monitoring are mandatory.
• Geriatric Use: Older patients should start at the lowest possible dose due to a higher likelihood of decreased renal function.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Current clinical research (2020–2026) has solidified Keveyis as a highly efficacious treatment for reducing the “attack burden” in periodic paralysis. In double-blind, placebo-controlled trials, patients treated with dichlorphenamide experienced a significant reduction in the number of weekly paralytic attacks compared to the placebo group.

Precise numerical data from clinical studies indicate that for patients with hypokalemic periodic paralysis, treatment with Keveyis resulted in a mean reduction of 2.3 attacks per week. For hyperkalemic patients, the reduction was similarly significant, often decreasing attack frequency by over 50%. Research results also show that beyond just the number of attacks, the severity of residual muscle weakness between episodes was notably improved.

Studies published between 2024 and 2026 have focused on “long-term metabolic targets,” showing that while the drug induces a consistent drop in serum bicarbonate (usually a reduction of 2 to 4 mEq/L), most patients maintain a stable compensated state. This consistent metabolic shift is directly correlated with the stabilization of muscle strength scores in over 70% of the treated population.

Safety Profile and Side Effects

There is currently no “Black Box Warning” for Keveyis. However, it is a sulfonamide derivative and must be avoided by patients with known sulfa allergies.

Common Side Effects (>10%)

• Paresthesia (tingling or “pins and needles” sensation in the extremities or face).
• Cognitive impairment (feelings of “brain fog,” confusion, or difficulty concentrating).
• Dysgeusia (altered sense of taste, particularly for carbonated beverages).
• Fatigue and muscle spasms.

Serious Adverse Events

• Severe Metabolic Acidosis: An excessive drop in blood pH that can lead to respiratory distress or cardiac arrhythmias.
• Hypokalemia: While used to treat periodic paralysis, the diuretic effect can sometimes cause dangerously low potassium levels.
• Nephrolithiasis: Increased risk of developing calcium phosphate kidney stones.
• Hypersensitivity: Severe skin reactions such as Stevens-Johnson Syndrome (rare).

Management Strategies: Regular monitoring of serum electrolytes and bicarbonate is essential. If paresthesia becomes intolerable, a slight downward dose titration is usually effective.

Research Areas

Direct Clinical Connections: Current research (2025–2026) is investigating the drug’s potential interaction with the Hypothalamic-Pituitary-Adrenal (HPA) axis. Because chronic metabolic acidosis can act as a systemic stressor, researchers are evaluating if long-term Keveyis use alters cortisol rhythms. Additionally, studies are looking into how carbonic anhydrase inhibition may protect against “insulin-induced” potassium shifts, which are a common trigger for paralytic attacks.

Generalization: Within the broader context of Endocrinology, active clinical trials are exploring the development of Biosimilars and second-generation inhibitors with fewer cognitive side effects. Advancements in Novel Delivery Systems, such as extended-release tablets, are being researched to provide more stable blood levels and reduce the paresthesia associated with rapid peak concentrations.

Severe Disease & Prevention: Extensive longitudinal studies are evaluating the drug’s efficacy in preventing “permanent interictal weakness”—a long-term complication where muscle strength fails to return even between attacks. By reducing the cumulative time muscles spend in a paralyzed state, Keveyis may prevent macrovascular and microvascular muscle tissue remodeling.

Disclaimer: The research described regarding Keveyis is currently exploratory and remains in early investigative and hypothesis-driven stages. These studies are not yet validated for routine clinical application and are not applicable to established or professional medical practice scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Complete metabolic panel (CMP) with a focus on serum potassium, sodium, and bicarbonate levels.
• Organ Function: Renal function (eGFR) and Hepatic enzyme monitoring to ensure clearance capability.
• Specialized Testing: Baseline arterial or venous blood gas (pH) to assess pre-existing acid-base status.
• Screening: Screening for a history of sulfa allergy and baseline cognitive assessment.

Monitoring and Precautions

• Vigilance: Monitoring for “therapeutic escape” (an increase in attacks after a period of stability) which may indicate worsening underlying metabolic demands or the need for dose adjustment.
• Lifestyle: Engagement in Medical Nutrition Therapy (MNT) is critical. Patients with the hypokalemic form should focus on a low-carbohydrate, low-sodium diet, while hyperkalemic patients must avoid high-potassium foods.
• “Do’s and Don’ts” list:
  • DO stay hydrated to reduce the risk of kidney stones.
  • DO report any new or worsening confusion or memory issues immediately.
  • DON’T consume high amounts of aspirin, as it can interact and increase the risk of toxicity.
  • DON’T skip blood tests for bicarbonate and potassium levels.

Legal Disclaimer

The medical information provided in this guide is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Keveyis is a specialized medication for rare metabolic disorders and must be used under the strict supervision of a board-certified Endocrinologist or Neurologist. Always consult your healthcare provider regarding any changes to your medication or diet. If you experience severe shortness of breath or sudden, extreme weakness, seek emergency medical attention immediately.